These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 1276479)
21. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. Lusher JM; Arkin S; Abildgaard CF; Schwartz RS N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474 [TBL] [Abstract][Full Text] [Related]
22. Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. A study of the cooperative group of hemophilia. Ambriz-Fernández R; Reyna-Fregoso MP; Pizzuto-Chávez J; Rodríguez-Moyado H; Farfán-Canto JM; Trueba-Christy E; Collazo-Jaloma J Arch Invest Med (Mex); 1985; 16(3):225-35. PubMed ID: 3938639 [No Abstract] [Full Text] [Related]
23. Anti-A in factor VIII concentrate: a cause of severe hemolysis in a patient with acquired factor VIII:C antibodies. Hach-Wunderle V; Teixidor D; Zumpe P; Kühnl P; Scharrer I Infusionstherapie; 1989 Jun; 16(3):100-1. PubMed ID: 2503450 [TBL] [Abstract][Full Text] [Related]
24. Retrospective study of inhibitor formation in Japanese hemophiliacs. Kamiya T; Takahashi I; Saito H Int J Hematol; 1995 Oct; 62(3):175-81. PubMed ID: 8589362 [TBL] [Abstract][Full Text] [Related]
25. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A. Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320 [TBL] [Abstract][Full Text] [Related]
26. Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Parker ET; Healey JF; Barrow RT; Craddock HN; Lollar P Blood; 2004 Aug; 104(3):704-10. PubMed ID: 15073030 [TBL] [Abstract][Full Text] [Related]
27. Characterization of an antibody to factor VIII in a patient with acquired hemophilia with circulating immune complexes. Ly B; Michaelsen TE; Dahl O; Frøland SS Scand J Haematol; 1982 Feb; 28(2):132-40. PubMed ID: 6806894 [TBL] [Abstract][Full Text] [Related]
28. Absence of blocking antibody in non-inhibitor haemophilic plasma. Pool J; Kaelin AC Thromb Haemost; 1977 Oct; 38(3):717-20. PubMed ID: 304261 [TBL] [Abstract][Full Text] [Related]
29. Studies on the neutralization of rabbit antibodies to human factor VIII. Kernoff PB; Kaelin AC Thromb Haemost; 1977 Oct; 38(3):707-16. PubMed ID: 74103 [TBL] [Abstract][Full Text] [Related]
30. Characterization of the immune response to factor VIII using hemophilia A* mice. Hoyer LW; Qian J Haematologica; 2000 Oct; 85(10 Suppl):100-2. PubMed ID: 11187859 [TBL] [Abstract][Full Text] [Related]
31. Characterization of factor VIII antibodies. Shapiro SS Ann N Y Acad Sci; 1975 Jan; 240():350-61. PubMed ID: 46139 [No Abstract] [Full Text] [Related]
32. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Whelan SF; Hofbauer CJ; Horling FM; Allacher P; Wolfsegger MJ; Oldenburg J; Male C; Windyga J; Tiede A; Schwarz HP; Scheiflinger F; Reipert BM Blood; 2013 Feb; 121(6):1039-48. PubMed ID: 23243272 [TBL] [Abstract][Full Text] [Related]
33. Effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII-antibody level. Lechner K; Nowotny C; Krinninger B; Zegner M; Deutsch E Thromb Haemost; 1979 Feb; 40(3):478-85. PubMed ID: 425062 [TBL] [Abstract][Full Text] [Related]
35. Elective cardiac operation in a patient with severe hemophilia and acquired factor VIII antibodies. Leggett PL; Doyle D; Smith WB; Culpepper W; Cooper S; Ochsner JL J Thorac Cardiovasc Surg; 1984 Apr; 87(4):556-60. PubMed ID: 6423912 [TBL] [Abstract][Full Text] [Related]
36. Circulating antibodies in factor VIII deficiency hemophilia: report of case. Cudzinowski L ASDC J Dent Child; 1979; 46(1):54-6. PubMed ID: 283081 [No Abstract] [Full Text] [Related]
37. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Ye P; Thompson AR; Sarkar R; Shen Z; Lillicrap DP; Kaufman RJ; Ochs HD; Rawlings DJ; Miao CH Mol Ther; 2004 Jul; 10(1):117-26. PubMed ID: 15233948 [TBL] [Abstract][Full Text] [Related]
38. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641 [TBL] [Abstract][Full Text] [Related]
39. Inhibitor development in a multitransfused patient with severe haemophilia A. van den Berg HM; Roosendaal G; Voorberg J; Mauser-Bunschoten EP Thromb Haemost; 1999 Jul; 82(1):151-2. PubMed ID: 10456472 [No Abstract] [Full Text] [Related]
40. [Treatment of hemorrhage in a patient with severe hemophilia A and factor VIII antibodies]. Gassmann AE; Kerkhofs H; Leeksma CH Schweiz Med Wochenschr; 1970 Oct; 100(41):1734-6. PubMed ID: 5480542 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]